| Status: Superseded | ||
AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE ISSUED DECEMBER 2017. Refer to TA494: Naltrexone–bupropion for managing overweight and obesity for full guidance on NICE recommendations, including any specific restrictions on the use of the technology. AWMSG documentation provided for reference only. |
||
|
||
Medicine details |
||
| Medicine name | naltrexone / bupropion (Mysimba®) | |
| Formulation | 8 mg / 90 mg prolonged-release tablet | |
| Reference number | 662 | |
| Indication | As an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in adult patients (≥ 18 years) with an initial body mass index of ≥ 30 kg/m² (obese), or ≥ 27 kg/m² to < 30 kg/m² (overweight) in the presence of one or more weight-related co-morbidities (e.g. type 2 diabetes, dyslipidaemia, or controlled hypertension) |
|
| Company | Orexigen Therapeutics Ireland Limited | |
| BNF chapter | Central nervous system | |
| Submission type | Non-submission | |
| Status | Superseded | |
| Ratification by Welsh Government | 15/07/2015 | |
| Date of issue | 16/07/2015 | |
| NICE guidance | TA494: Naltrexone–bupropion for managing overweight and obesity |
|